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HIGHLIGHTS
• Since the geopolitical developments of 1989, former centrally planned economies of
Eastern Europe followed distinctively different pathways in national pharmaceutical
expenditure evolution as compared to their free market Western European
counterparts.
• Long term spending on pharmaceuticals expressed as percentage of total health
expenditure was falling in free market economies as of 1989. Back in early 1990s it
was at higher levels in transitional Eastern European countries and actually continued
to grow further.
• Public financing share of total pharmaceutical expenditure was steadily falling in most
Central and Eastern European countries over the recent few decades. Opposed
scenario were EU-15 countries which successfully increased their public funding of
prescription medicines for the sake of their citizens.
• Pace of annual increase in per capita spending on medicines in PPP terms, was at
least 20% faster in Eastern Europe compared to their Western counterparts. During the
same years, CEE region was expanding their pharmaceuticals share of health spending
in eight fold faster annual rate compared to the EU 15.
• Private and out-of-pocket expenditure became dominant in former socialist countries.
Affordability issues coupled with growing income inequality in transitional economies
will present a serious challenge to equitable provision and sustainable financing of
pharmaceuticals in the long run.
Keywords: Eastern Europe, Western Europe, centrally-planned economy, free market economy, pharmaceuticals,
expenditure, spending, transition
JEL codes: I11 Analysis of Health Care Markets, I18 Government Policy Regulation Public Health, P2 Socialist
Systems and Transitional Economies, P1 Capitalist Systems, P51 Comparative Analysis of Economic Systems, F6
Economic Impacts of Globalization
INTRODUCTION
Historical decades following WWII were marked with rapid industrialization and build-up of
welfare states in most free-market economies. This trend was closely associated with health
expenditures rising across 4% GDP threshold which remained quite stable throughout entire
XIX and first half of XX century (Getzen, 1990). After this phenomenon was described in the
US it became common elsewhere but most prominent in Western Europe, Japan and British
Commonwealth countries. Over the next half a century health expenditure doubled or even tripled
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in many of the richest OECD societies. Challenges to
sustainability of health care funding gradually were more
obvious and concerning for policy makers. Unlike capital
investments in buildings, equipment, medical staff salaries
etc. prescription and dispensing of pharmaceuticals soon was
understood to be more manageable part of these costs (Carone
et al., 2012).
European geopolitical destiny since the end of Cold War Era
back in 1989 opened up many issues ultimately affecting costs
of medical care provision. Large number of previously state
controlled socialist economies have undergone profound health
reforms adopting free-market model (Jakovljevic, 2013). Central
and Eastern European Post-Semashko Soviet style health systems
were characterized with higher number of (more) hospital beds,
physician, and nursing staff densities compared to Western
Europe (Semashko, 1934; Torosyan et al., 2008). Nevertheless,
average length of hospital stay was much lengthier and these
nations had curative, hospital based systems instead of preventive
ones, driven by family medicine practices common in the West
(Healy and McKee, 2002). The latter turned out to be far more
effective in terms of resource use and health outcomes gained
(Kornai and Eggleston, 2001).
Evidence based medicine and cost-effective resource
allocation slowly became more common in Eastern European
policy makers mindset (Jakovljevic et al., 2011). These changes
were closely to the rapid growth of most CEE pharmaceutical
markets since the middle 1990s and early 2000s (Jakovljevic
et al., 2015a). Although drug acquisition costs clearly grew up in
the old EU-15 pre-2004 members as well, this appears to have
happened at the far slower pace (Nuijten et al., 2001). Basically
similar upward trends in value based turnover and budget impact
of medicines in East and West of European region were hiding
distinctively different patterns. We decided to observe WHO
issued European Health for All database (HFA-DB) in order to
test this assumption.
DATA REPORT METHODS
Public Data Sources Used
WHO issued European Health for All database (HFA-DB) is
a public registry with large number of data on demographics,
health care resources and outcomes and medical service
consumption data on all countries of the European Region
(WHO, HFA-DB, 2015). It consists of regularly updated reports
issued by WHO/European Office, the statistical office of the
European Union (EUROSTAT), United Nations system, the
Organization for Economic Cooperation and Development and
data reported by the national authorities. Readers are free to
access and reuse these publicly available data at the link provided
beneath.
Data
Pharmaceutical spending is commonly defined as expenditures
on prescription medicines and over-the-counter products
without hospital consumption of pharmaceuticals (OECD
Pharmaceutical Spending, 2013). Medical consumables are
included in such data in many countries (approximately 5% of
reported value) and pharmacists’ salaries if these are accounted
separately from the price of medicines. Ultimately calculated
total pharmaceutical expenditure assumes wholesale and retail
margins and value-added tax.
Selected pharmaceutical spending indicators in this study
were: Pharmaceutical expenditure expressed as percentage of
total health expenditure, public pharmaceutical expenditure
expressed as percentage of total pharmaceutical expenditure and
pharmaceutical expenditure per capita expressed in purchase
power parity terms (international $). Time horizon observed
was spreading from the earliest available evidence listed in HFA-
DB back in 1970 to the last official updates in 2012.Targeted
countries where were all 53 countries of the European Region
divided in two groups based on their economic and health
care historical legacies: free-market economies prior to 1989
(a total of 25dominantly Western European countries) and
centrally planned socialist economies prior to 1989 (a total of
28dominantly Eastern European countries; Berend, 2006).Total
of five nations among free-market economies and ten among
former centrally planned economies were observed for missing
relevant data and thus were excluded from observation.
RESULTS
Pharmaceutical expenditure (PE) percentage of total health
expenditure used to be higher in centrally planned economies.
Mean of historical bottom values was 20% growing toward
21.7% in recent years. This meant total +3.0% net increase per
country over 14.7 years long time horizon on average. Mean
annual growth was calculated to be +0.08%. Unlike these, we
notice exactly the opposed trend in free market economies.
Their arithmetic mean of historical baseline values was 16.2%.
It felt toward 15.1% in contemporary period. Net change here
was negative: average −0.7% decrease over 33.5 years long time
horizon on average. Length of observation here was longer
because OECD economies pioneered reporting these data to
WHO during the Cold War Era. Their mean annual growth was
eight times slower, approximately+0.01%.
Observing the landscape of public pharmaceutical
expenditure percentage point share of total health expenditure
we come to entirely different mirror-like reflection. Centrally
planned economies tended to have lower public participation
in drug acquisition and dispensing costs (arithmetic mean of
earliest reported values of 43.3%) which was historically further
falling toward 36.5% on average in recent years. This meant
a total contraction of public spending on drugs of −6.8% on
average. This huge change happened over the course of 10.6
years (mean time span between first and last reported values in
Eastern European states).This accounts for mean annual−0.47%
contraction of public spending on drugs. Free market nations
recorded much higher average public share of 57.5% in earliest
historical records back in 1970s. It has grown further up to
62.9% in recent years with a total net change of +5.4% over 32.3
years (mean time span between first and last reported values in
Western, Southern and Northern European states). Annual net
change was positive amounting to +0.16%. This huge disparity
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presents the single most important finding of this data report
(see Figure 1).
Pharmaceutical expenditure per capita expressed in
purchase power parity (PPP) terms (international $) allows
for international comparability and these values introduce
another perspective. Back in early 1970s free market economies
were spending on medicines modest average amount of $68 per
capita which grew tremendously reaching mean value of $488 in
recent years. This meant net gain of $420 on average with annual
increment of +$12.30 over 34.1 years (Table 1). Among most of
the former centrally planned economies such data were lacking
almost until the late 1990s. Therefore, we have come to a slightly
distorted picture of mean $190 per capita among the earliest
reported values rising up to $427 in recent years. Total increment
of some $237 was approximately twice lower compared to the
West. Keeping in mind that this change refers to the average
time span of 13.8 years between the earliest and last reported
values, we come to the annual increment of +$16.89 per capita
(Table 2).
DISCUSSION
Long term spending on pharmaceuticals expressed as percentage
of total health expenditure was falling in mature economies
(Mossialos and Oliver, 2005).Back in the late 1980s and early
1990s it was at higher levels in transitional Eastern European
countries and actually continued to grow (Mrazek et al.,
2004). Opposed to this trend, free market, predominantly
Western, Southern and Northern European states continued to
contract participation of medicines in their national medical
spending pattern. This effectively meant that other medical
technologies mostly related to hospital care, such as radiology
diagnostics, advanced surgery, interventional radiology and
radiation oncology, laboratory tests, rehabilitating and mental
health related medical services and social support programs
were participating more significantly to the structure of medical
spending (Robinson, 1994; Ackroyd et al., 2006; Jakovljevic et al.,
2013, 2014a, 2015b; Rankovic´ et al., 2013).
FIGURE 1 | Annual Increment—Pharmaceutical Expenditures (%)
change (observation time span up to 22 years among former centrally
planned and up to 42 years in free market economies).
Public financing share of total pharmaceutical expenditure
was steadily falling in most Central and Eastern European
countries (Gotseva, 2015). It was at far lower, approximately
one-third level, compared to their Western counterparts back
in Cold War era (Jakovljevic et al., 2015d). Today, such changes
coupled with rising budget impact of drug acquisition costs point
out to the strong growth of patient cost-sharing mechanisms
throughout the CEE region (Iskrov and Stefanov, 2015; Tambor
et al., 2015). Out-of-pocket expenses and risks of catastrophic
illness-induced household expenditure add to the complexity of
this challenge (Jakovljevic, 2014a,b).
Opposed scenario were EU-15 countries successfully
struggling to maintain and increase their public funding of
prescription medicines for the sake of their citizens. They
achieved extension in population coverage with cost-effective
drug reimbursement strategies (Rémuzat et al., 2015). Thus, these
countries were reducing exposure of vulnerable social groups
to the issues affecting access to medicines. Although success
rates across EU-15 differ significantly, most countries have
adopted responsible pharmaceutical polices. National authorities
besides, proved mostly capable of withstanding diverse financial
constraints. Some were temporary such as the global economic
recession while others such as medical innovation led primarily
by brand pharmaceutical industry posed difficulties in the long
run (Higgins and Graham, 2009; Dagovic et al., 2015). Huge
budget impact of novel medicines such as monoclonal antibodies
remains particularly hot topic sparkling debate among policy
makers (Jakovljevic, 2014b).Some of the solutions found to
release such pressures were incentives for generic substitution of
brand name medicines (Jakovljevic et al., 2014b). With more or
less legislative obstacles generic share in local markets expanded
significantly over time (Simoens and De Coster, 2006).
Per capita spending on pharmaceuticals expressed in
purchased power parity terms, points out to the joint strong
growth of overall costs of prescribed and dispensed medicines
and OTC agents (Ess et al., 2003). With regards to the historical
perspective there appears to be no distinct difference in spending
patterns among the two regions. The obvious fact was lag
in Eastern European drug acquisition costs back in the late
1980s (Rhodes et al., 1999). Rapid increase in pharmaceutical
expenditure since the 1990s followed, being one of the recognized
mile stones of transitional health care reforms (Krajewski-Siuda
and Romaniuk, 2006). Notable transformation of local CEE
markets is the expanded presence of brand name medicines and
diversification of payment mechanisms (Petrusic and Jakovljevic,
2015). Informal payments and widening income gaps affecting
affordability of medicines remain the key challenges across the
region (Ensor, 2004; Jakovljevic et al., 2015c).
STUDY LIMITATIONS
Some countries did not report official data on pharmaceutical
spending for either some indicators or years within the time span
observed. These missing data refer to a total of 5 nations among
free-market economies and 10 countries among former centrally
planned economies. Most cases of partially or entirely missing
data refer to the countries with relatively small population size in
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respective groups. Notable exceptions from this rule are Romania
and Russian Federation. Russia was classified as a high income
economy by theWorld Bank since August 2013 and as one of top
performing emerging BRICS markets (The World Bank, 2015;
Jakovljevic, 2016). Due to these facts we would like to limit our
results and conclusions on the rest of Eastern European region as
thus there is higher degree of homogeneity. Countries presented
in the observed sample (20 of historical free market and 18
of centrally planned economies) are geographically scattered
throughout the respective European regions. Therefore, we still
regard observed sample of countries to be representative of broad
long term trends in pharmaceutical spending in the European
Region.
CONCLUSION
The two observed broad groups of countries, former centrally
planned and free market economies, share profoundly different
historical legacies in medicines provision and financing
mechanisms (Mossialos et al., 2004). This data report provides
insight into the existence of two distinctively different pathways
in spending on drugs over past several decades in the East and
West of Europe. National policies sharing public reimbursement,
insurance based mechanisms and out-of-pocket spending appear
to be headed in two different directions (Mackenbach, 2006).
Eastern European states struggle with affordability issues and
unequal access to medicines mostly determined by household
income groups. Single most concerning fact is that transitional
economies contracted their public share of pharmaceutical
expenditure for almost half of percentage over the long course of
years. Traditional free market economies, primarily EU-15 states
mostly achieved better protection for their poor and vulnerable
patient groups including those suffering from rare diseases and
those requiring expensive treatment strategies (Iskrov et al.,
2012). Nevertheless, we must point out the huge progress that
was made in Eastern Europe providing access to the innovative
medicines to the broad layers of population (Putrik et al., 2014).
Pace of annual increase in per capita spending on medicines in
PPP terms, was at least 20% faster in Eastern Europe compared
to theirWestern counterparts. During the same years CEE region
was expanding their pharmaceuticals share of health spending
in eight fold faster annual rate compared to the EU 15. Current
difficulties to withstand pressures arising from population aging
and prosperity diseases remain primary challenge for sustainable
funding of medicines provision in all of Europe (Ogura and
Jakovljevic, 2014; Jakovljevic and Milovanovic, 2015; Jakovljevic
and Laaser, 2015). Although differences remain we believe that
at some point in future, these regions will converge increasing
social welfare and affordability of medicines to the ordinary
citizens (Deacon, 2000).
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